Expanding the Evidence on Lung Cancer Prevention

Researchers are investigating whether interventions like metformin, exercise, and GLP-1 receptor agonists can mitigate the effects of obesity on lung cancer development. Clinical trials are being proposed to validate findings from preclinical animal studies in human populations.
Why it matters
Identifying effective interventions for obesity-related cancer could significantly improve prevention strategies and patient outcomes across various cancer types.
In an interview with Targeted Onc™, Sai Yendamuri, MD, MBA, FACS, discusses emerging research investigating whether interventions targeting obesity can reverse its effects on lung cancer development and progression. He highlights a recently completed clinical trial evaluating metformin, a commonly used medication, to determine whether it can counteract the adverse effects of obesity. Researchers are currently analyzing the data, with results expected by the end of the year.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in